분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2016-03-14 13:54:53 , Hit : 700
 Tunable Form of CRISPR Is an Efficient Regulator of Stem Cell Expression


GEN News Highlights

Mar 11, 2016

Combining powerful technologies in biology can often have an exceptionally synergistic effect that leads to fundamental breakthroughs in how researchers look at normal metabolic pathways or aberrant disease states. This is what researchers from the Gladstone Institute hope will emerge from their recent use of a relatively new variation of the CRISPR-Cas9 system on the genome of induced pluripotent stem cells (iPSCs)—offering a significant technological advance in creating cell models of genetic diseases.    

In the newly published study, researchers used a modified version of CRISPR called CRISPR interference (CRISPRi) to inactivate genes in iPSCs and heart cells created from iPSCs. The method, first reported in 2013 by Stanley Qi, Ph.D., who is a co-author on the current paper, significantly improves the original CRISPR-Cas9 system by allowing genes to be silenced more precisely and efficiently. Additionally, CRISPRi also offers the flexibility of reversing and carefully controlling the amount of gene suppression.

The standard CRISPR system uses the Cas9 protein to delete a precise part of the genome through small cuts in a cell's DNA. CRISPRi builds on this technology by using a special deactivated version of the Cas9 protein along with an additional inhibitor protein, Krüppel-associated box, or KRAB. Together, these proteins sit at the target spot on the genome and suppress gene expression without excising the DNA.

“We developed clustered regularly interspaced short palindromic repeat interference (CRISPRi) to repress gene expression in human induced pluripotent stem cells (iPSCs),” the authors wrote. “CRISPRi, in which a doxycycline-inducible deactivated Cas9 is fused to a KRAB repression domain, can specifically and reversibly inhibit gene expression in iPSCs and iPSC-derived cardiac progenitors, cardiomyocytes, and T lymphocytes. This gene repression system is tunable and has the potential to silence single alleles.”

Surprisingly the investigators found that temporarily silencing gene expression in this manner was much more consistent than permanently cleaving the genome.

"We were amazed by the dramatic difference in performance between the two systems," remarked senior study author Bruce Conklin, M.D., senior investigator at the Gladstone Institute of Cardiovascular Disease and Roddenberry Stem Cell Center. "We thought that permanently cutting the genome would be the more effective way to silence a gene, but in fact, CRISPRi is so precise and binds so tightly to the genome that it is actually a better way to silence a gene."

In the current study, the Gladstone scientists compared how well CRISPRi and CRISPR-Cas9 silenced a particular gene that controls iPSC pluripotency. They discovered that CRISPRi was much more efficient than CRISPR-Cas9, because, in 95% of the cells created using CRISPRi, the target gene was silenced, compared to only 60–70% of cells grown from traditional CRISPR-Cas9 editing. Moreover, CRISPRi also did not cause any off-target changes in gene expression, like undesired insertions or deletions to the cell's genome, which is typically a cause for concern with CRISPR-Cas9.

The findings from this study were published recently in Cell Stem Cell in an article entitled “CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs.”

Another advantage of CRISPRi is that it can act as a toggle switch, enabling the scientists to reverse gene suppression by simply removing the chemical that turns on the gene inhibitor. In the current study, the researchers were able to tune how much they silenced a gene by changing the amount of the chemicals they added. Both of these results support much more versatile investigations into the role of individual genes that affect development and disease.

"CRISPRi holds a major advantage in making disease-relevant cell types," explained lead author Mohammad Mandegar, D.Phil., research scientist at Gladstone. "Using this technology, we can mimic disease in a homogeneous population of heart cells created from iPSCs. This development allows us to study genetic diseases more easily and potentially identify new therapeutic targets."







947   바이오통신원 [바이오토픽] 이제는 염기편집 시대, Cas9를 변형하여 DNA 한 글자만 바꾼다.  이성욱 2016/04/21 1171
946   Hitting HIV with CRISPR/Cas9 Can Arouse Resistance  이성욱 2016/04/10 866
945   GSK Gets Positive CHMP Opinion For Strimvelis To Treat Rare Disease ADA-SCID  이성욱 2016/04/02 1036
944   CRISPR Can Tag RNA  이성욱 2016/03/26 801
943   미니멀세포(minimal cell)를 만든 크레이그 벤터  이성욱 2016/03/26 956
942   Minimal Genome Created  이성욱 2016/03/26 833
941   Using Gene Editing to Delete HIV from Human T Cells  이성욱 2016/03/23 775
940   RNA May Surpass DNA in Precision Medicine  이성욱 2016/03/23 821
939   Zika Update  이성욱 2016/03/15 756
938   CRISPR/Cas9을 이용하여 PRRS 바이러스에 감염되지 않는 돼지를 개발하다  이성욱 2016/03/14 1204
937   유전자 가위, 매머드 복원-안전한 백신의 시대 리본 자르다  이성욱 2016/03/14 991
  Tunable Form of CRISPR Is an Efficient Regulator of Stem Cell Expression  이성욱 2016/03/14 700
935   NIH 연구진들은 5가지 종류의 암에서 공유되는 충격적인 게놈 상의 특징을 확인  이성욱 2016/03/09 829
934   특허전쟁: 미국 특허청, CRISPR의 특허권 중재 시작  이성욱 2016/03/08 1049
933   CRISPR Editing of Human Embryos Approved in the U.K.  이성욱 2016/02/02 808
932   CRISPR Fixes Stem Cells Harboring Blindness-Causing Defect  이성욱 2016/02/01 763
931   거대 바이러스에게서도 발견된 CRISPR 유사 시스템  이성욱 2016/03/02 1123
930   MIT 선정 2015년 주목받은 Biomedicine 뉴스  이성욱 2016/02/03 889
929   유전자치료제 연구개발 및 규제 동향 2015-식품의약품안전처  이성욱 2016/01/20 1067
928   융합연구리뷰 | Convergence Research Review  이성욱 2016/01/08 1058

[이전 10개] [1]..[11][12][13][14][15][16] 17 [18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN